India · Delayed Price · Currency is INR NSE:JBCHEPHARM Statistics
Total Valuation
NSE:JBCHEPHARM has a market cap or net worth of INR 348.75 billion. The enterprise value is 336.57 billion.
| Market Cap | 348.75B |
| Enterprise Value | 336.57B |
Important Dates
The last earnings date was Monday, May 11, 2026.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
| Current Share Class | 160.56M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | +0.91% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 31.02% |
| Float | 81.52M |
Valuation Ratios
The trailing PE ratio is 49.16 and the forward PE ratio is 39.19.
| PE Ratio | 49.16 |
| Forward PE | 39.19 |
| PS Ratio | 8.41 |
| PB Ratio | 8.38 |
| P/TBV Ratio | 12.14 |
| P/FCF Ratio | 56.18 |
| P/OCF Ratio | 49.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.47, with an EV/FCF ratio of 54.22.
| EV / Earnings | 47.44 |
| EV / Sales | 8.11 |
| EV / EBITDA | 30.47 |
| EV / EBIT | 36.47 |
| EV / FCF | 54.22 |
Financial Position
The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.92 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.01 |
| Interest Coverage | 185.45 |
Financial Efficiency
Return on equity (ROE) is 18.69% and return on invested capital (ROIC) is 22.20%.
| Return on Equity (ROE) | 18.69% |
| Return on Assets (ROA) | 12.48% |
| Return on Invested Capital (ROIC) | 22.20% |
| Return on Capital Employed (ROCE) | 21.08% |
| Weighted Average Cost of Capital (WACC) | 4.05% |
| Revenue Per Employee | 7.40M |
| Profits Per Employee | 1.27M |
| Employee Count | 5,602 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, NSE:JBCHEPHARM has paid 2.43 billion in taxes.
| Income Tax | 2.43B |
| Effective Tax Rate | 25.50% |
Stock Price Statistics
The stock price has increased by +28.06% in the last 52 weeks. The beta is -0.04, so NSE:JBCHEPHARM's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +28.06% |
| 50-Day Moving Average | 2,082.57 |
| 200-Day Moving Average | 1,885.50 |
| Relative Strength Index (RSI) | 56.24 |
| Average Volume (20 Days) | 338,041 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JBCHEPHARM had revenue of INR 41.48 billion and earned 7.09 billion in profits. Earnings per share was 44.45.
| Revenue | 41.48B |
| Gross Profit | 28.11B |
| Operating Income | 9.23B |
| Pretax Income | 9.52B |
| Net Income | 7.09B |
| EBITDA | 10.91B |
| EBIT | 9.23B |
| Earnings Per Share (EPS) | 44.45 |
Balance Sheet
The company has 12.21 billion in cash and 35.89 million in debt, with a net cash position of 12.18 billion.
| Cash & Cash Equivalents | 12.21B |
| Total Debt | 35.89M |
| Net Cash | 12.18B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 41.59B |
| Book Value Per Share | 259.05 |
| Working Capital | 23.18B |
Cash Flow
In the last 12 months, operating cash flow was 7.04 billion and capital expenditures -831.89 million, giving a free cash flow of 6.21 billion.
| Operating Cash Flow | 7.04B |
| Capital Expenditures | -831.89M |
| Depreciation & Amortization | 1.68B |
| Net Borrowing | -387.21M |
| Free Cash Flow | 6.21B |
| FCF Per Share | n/a |
Margins
Gross margin is 67.77%, with operating and profit margins of 22.25% and 17.10%.
| Gross Margin | 67.77% |
| Operating Margin | 22.25% |
| Pretax Margin | 22.96% |
| Profit Margin | 17.10% |
| EBITDA Margin | 26.30% |
| EBIT Margin | 22.25% |
| FCF Margin | 14.97% |
Dividends & Yields
This stock pays an annual dividend of 22.00, which amounts to a dividend yield of 1.01%.
| Dividend Per Share | 22.00 |
| Dividend Yield | 1.01% |
| Dividend Growth (YoY) | 41.94% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 44.16% |
| Buyback Yield | -0.59% |
| Shareholder Yield | 0.42% |
| Earnings Yield | 2.03% |
| FCF Yield | 1.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:JBCHEPHARM is 2,258.22, which is 3.59% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,258.22 |
| Price Target Difference | 3.59% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 11.22% |
| EPS Growth Forecast (3Y) | 21.60% |
Stock Splits
The last stock split was on September 18, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 18, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
NSE:JBCHEPHARM has an Altman Z-Score of 23.55 and a Piotroski F-Score of 5.
| Altman Z-Score | 23.55 |
| Piotroski F-Score | 5 |